Nanomedicine for improvement of dendritic cell-based cancer immunotherapy
Vida Hashemi(University of Maragheh), Farhad Jadidi‐Niaragh(Tabriz University of Medical Sciences), Afshin Namdar(University of Alberta), Hamed Mohammadi(Tehran University of Medical Sciences), Brinton Seashore‐Ludlow(Karolinska Institutet), Mitra Ghasemi Chaleshtari(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Shohreh Farhadi(Shahid Beheshti University of Medical Sciences), Ghasem Ghalamfarsa(Yasuj University of Medical Sciences), Amir Ajjoolabady(Tabriz University of Medical Sciences), Ali Masjedi(Tabriz University of Medical Sciences)
Cited by 44
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
The paradox of Th17 cell functions in tumor immunity
|Cellular Immunology|2017|222
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202